
Crescenzio Scioscia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7632238/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of etanercept in the treatment of dermatomyositis: a case series. Journal of Rheumatology, 2006, 33, 1802-4.	1.0	82
2	The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study. Annals of the Rheumatic Diseases, 2018, 77, 1283-1289.	0.5	62
3	Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine, 2015, 82, 187-191.	0.8	58
4	Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. Rheumatology, 2017, 56, 1518-1532.	0.9	56
5	Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis and Rheumatism, 2005, 52, 2519-2520.	6.7	48
6	Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. Rheumatology, 2016, 55, 1826-1836.	0.9	36
7	Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scandinavian Journal of Rheumatology, 2015, 44, 192-199.	0.6	30
8	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. Mediators of Inflammation, 2018, 2018, 1-7.	1.4	30
9	Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism. Annals of the Rheumatic Diseases, 2005, 64, 217-221.	0.5	29
10	Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Scandinavian Journal of Rheumatology, 2013, 42, 41-44.	0.6	29
11	Leucocytoclastic vasculitis as onset symptom of ulcerative colitis. Annals of the Rheumatic Diseases, 2003, 62, 785-786.	0.5	28
12	Old and New Antirheumatic Drugs and the Risk of Hepatotoxicity. Therapeutic Drug Monitoring, 2012, 34, 622-628.	1.0	28
13	Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clinical Rheumatology, 2018, 37, 667-675.	1.0	28
14	Ultrasonography in psoriatic arthritis: which sites should we scan?. Annals of the Rheumatic Diseases, 2018, 77, 1537-1538.	0.5	18
15	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA). Reumatismo, 2016, 68, 126-136.	0.4	15
16	Lipid Profile of Rheumatoid Arthritis Patients Treated with Antiâ€Tumor Necrosis Factorâ€Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response. Drug Development Research, 2014, 75, S77-80.	1.4	13
17	Ultrasonography in the diagnosis and management of patients with inflammatory arthritides. European Journal of Internal Medicine, 2014, 25, 103-111.	1.0	13
18	Influence of TNF-α inhibition on oxidative stress of rheumatoid arthritis patients. Reumatismo, 2015, 67, 97-102.	0.4	12

#	Article	IF	CITATIONS
19	The Italian MSUS Study Group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatology. Rheumatology, 2014, 53, 367-373.	0.9	10
20	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clinical Rheumatology, 2014, 33, 31-37.	1.0	10
21	A knowledge-based framework enabling decision support in RFID solutions for healthcare. , 2010, , .		5
22	Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. Journal of International Medical Research, 2016, 44, 28-32.	0.4	5
23	Knowledge-Based Decision Support in Healthcare via Near Field Communication. Sensors, 2020, 20, 4923.	2.1	5
24	Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy. Clinical Rheumatology, 2016, 35, 1923-1929.	1.0	4
25	Refractory knee giant cell tumor of the synovial membrane treated with intraâ€articular injection of Infliximab: a case series and review of the literature. International Journal of Rheumatic Diseases, 2015, 18, 908-912.	0.9	2
26	Response of Cartilage Oligomeric Matrix Protein to Monoclonal Antibody Drugs in Patients with Rheumatoid Arthritis. Laboratory Medicine, 2009, 40, 645-650.	0.8	1
27	OP0217â€Ultrasound-Detected Synovitis and Tenosynovitis Independently Associate with Flare in Patients with Rheumatoid Arthritis in Clinical Remission. Annals of the Rheumatic Diseases, 2015, 74, 153.1-153.	0.5	1
28	SAT0216â€Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings. Annals of the Rheumatic Diseases, 2016, 75, 747.1-747.	0.5	1
29	Rheumatic diseases during pregnancy and SARSâ€CoVâ€2: An appeal for medication adherence. International Journal of Gynecology and Obstetrics, 2020, 150, 269-270.	1.0	1
30	Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity. Rheumatology, 2022, 62, 116-123.	0.9	1
31	AB0561â€Risk of HBV infection reactivation in patients with rheumatoid arthritis undergoing treatment with ANTI-CD20 (RITUXIMAB). Annals of the Rheumatic Diseases, 2013, 71, 670.10-670.	0.5	0
32	AB0578â€Anti-tnfa therapy in psoriatic arthritis: different rate of remission in polyarticular and oligoarticular subsets. Annals of the Rheumatic Diseases, 2013, 72, A966.3-A966.	0.5	0
33	AB1114â€Three Years Experience with "Sustainâ€; an Extra-Hospital Infusion Programme for Patients with Rheumatoid Arthritis Treated with Abatacept. Annals of the Rheumatic Diseases, 2014, 73, 1170.2-1170.	0.5	0
34	AB0065â€Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease. Annals of the Rheumatic Diseases, 2015, 74, 912.2-912.	0.5	0
35	AB0452â€Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1. Annals of the Rheumatic Diseases, 2015, 74, 1046.3-1047.	0.5	0
			_

L'obésité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après échec 36 d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition) Tj ETQapO 0 0 rgBT /Overlo

3

CRESCENZIO SCIOSCIA

#	Article	IF	CITATIONS
37	SAT0212â€Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines. Annals of the Rheumatic Diseases, 2016, 75, 745.2-745.	0.5	Ο
38	AB0041â€Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study. Annals of the Rheumatic Diseases, 2016, 75, 911.1-911.	0.5	0
39	AB0618â€A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases. , 2017, , .		0
40	FRI0110â€Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts. , 2017, , .		0
41	SAT0380â€FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS. , 2019, , .		0
42	AB0245â€PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTI REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE). , 2019, , .	ER	0
43	Economical Evaluation of the Sustain Program for the Out-of-Hospital Administration of Abatacept for Rheumatoid Arthritis. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000236.	0.2	0
44	THU0153â€The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients. , 2018, , .		0
45	AB0836â€Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study. , 2018, , .		0
46	AB0369â€Adult-onset still's disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience. , 2018, , .		0
47	OP0129â€Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors. , 2018, , .		0
48	THU0168â€Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis. , 2018, , .		0